NCT06782685View on ClinicalTrials.gov

Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

138

Participants

Timeline

Start Date

June 23, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

March 31, 2027

Conditions
Advanced Pancreatic Cancer (Part 1)
Interventions
DRUG

Irinotecan liposoma

Exploration started with 50mg/m\^2 dose, preset 50mg/m\^2, 60mg/m\^2, 2 dose groups, IV infusion 90min, d1

DRUG

oxaliplatin

Exploration started with 60mg/m\^2 dose, preset 60mg/m\^2, 85mg/m\^2, 2 dose groups, IV infusion, d1

DRUG

bevacizumab

5mg/kg，i.v.，d1

DRUG

5-FU

2400mg/m\^2, i.v.，46h

DRUG

LV

400mg/m\^2, i.v.，d1

DRUG

Irinotecan Liposomal

70mg/m\^2, i.v.，d1

DRUG

Irinotecan Liposomal

Phase II recommended dose

DRUG

Oxaliplatin

Phase II recommended dose

Trial Locations (2)

Unknown

NOT_YET_RECRUITING

Beijing, Beijing

RECRUITING

Chinese PLA General Hospital, Beijing

All Listed Sponsors
lead

Dai, Guanghai

OTHER